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NEW IN 2016, UPDATE OF POLISH FORUM FOR  
PREVENTION GUIDELINES ON DYSLIPIDAEMIA
1. New data on epidemiology of dyslipidaemia in the 
Polish population
2. New treatment goals for low-density lipoprotein choles-
terol (LDL-C) in high- and very high-risk groups
3. Indications for the use of inhibitors of proprotein con-
vertase subtilisin/kexin type 9 (PCSK9)
4. Assessment of alanine aminotransferase (ALT) and cre-
atine kinase (CK) before starting statins
5. No need for routine monitoring of ALT and CK during 
statin therapy
1. DYSLIPIDAEMIA — DEFINITION 
The characteristic feature of dyslipidaemia is abnormal concen-
tration of one or more lipoprotein fractions or their composition 
in serum in the fasting state. In clinical practice, dyslipidaemias 
are defined on the basis of the laboratory test results [1–3]:
 — hypercholesterolaemia — total cholesterol concentra-
tion (TC) ≥ 5.0 mmol/L (≥ 190 mg/dL) and (or) LDL-C 
concentration ≥ 3.0 mmol/L (≥ 115 mg/dL);
 — hypertriglyceridaemia — triglyceride concentration (TG) 
≥ 1.7 mmol/L (≥ 150 mg/dL); severe hypertriglyceridae-
mia is defined as triglyceride concentration > 10 mmol/L 
(> 900 mg/dL);
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 — low high density lipoprotein cholesterol (HDL-C) 
concentration < 1 mmol/L (< 40 mg/dL) in men and 
< 1.2 mmol/L (< 45 mg/dL) in women;
 — mixed hyperlipidaemia — increased LDL-C and TG 
levels with frequently decreased HDL-C level.
2. ETIOPATHOGENESIS OF DYSLIPIDAEMIA
Primary dyslipidaemia is usually caused by environmental 
factors (such as unhealthy diet, low physical activity, smok-
ing) and genetic predisposition. Primary dyslipidaemia also 
includes heterozygous familial hypercholesterolaemia (FH) 
characterised by a prominent tendency to develop premature 
atherosclerosis (it can be suspected if the concentration of TC 
is ≥ 320 mg/dL) [2].
Secondary dyslipidaemia may occur in hypothyroidism, 
cholestatic jaundice, primary biliary cirrhosis, kidney disease, 
obesity, diabetes, multiple myeloma, bulimia, and lipodys-
trophy and when using corticosteroids, immunosuppressing 
drugs, and oestrogens, especially oral, cyclosporine, some 
beta-blockers, thiazide diuretics, protease inhibitors, and 
retinoids [2, 3].
3. EPIDEMIOLOGY
In the Polish adult population (age ≥ 20 years) hypercholes-
terolaemia occurs in 70% of men and in 64% of women (67% 
on average). Most of them (61%) are not aware of having the 
condition, and an additional 17% are aware but are not treated 
for it. Only 6% are treated and reach the treatment target. Ad-
ditionally, hypertriglyceridaemia with normal concentration of 
TC occurs in 6% of men and in 2% of women, and low levels of 
HDL-C in persons with normal TC and TG occurs in 5% and 7%, 
respectively. In total, 77% of the Polish adult population (proxi-
mately 23.5 million) have one or more forms of dyslipidaemia, 
which increases cardiovascular risk. Although the prevalence of 
hypercholesterolaemia did not change significantly in the last 
decade, the prevalence of hypertriglyceridaemia (in men) and 
the prevalence of low HDL-C (both sexes) increased, reflecting 
unfavourable lifestyle changes in Polish adults [4].
4. CARDIOVASCULAR DISEASE RISK 
Cardiovascular disease (CVD) risk is increased in hypercholes-
terolaemia, low HDL-C concentration, and to a lesser extent 
in hypertriglyceridaemia, which, if severe, is also a risk factor 
for acute pancreatitis [2]. Every 1.0 mmol/L (40 mg/dL) reduc-
tion in LDL-C is associated with a corresponding decrease 
in major cardiovascular events by 23%, stroke incidence by 
17%, coronary disease mortality by 20%, and overall mortal-
ity by 10% [5].
5. SCREENING FOR DYSLIPIDEMIA (LIPID PROFILE)
Lipid analysis is recommended along with the evaluation 
of other risk factors in men ≥ 40 years of age and in wom-
en ≥ 50 years of age or after menopause. Determination of 
lipid profile is always recommended in the case of: the oc-
currence of CVD, diabetes, hypertension, obesity, cigarette 
smoking, chronic kidney disease, chronic inflammatory dis-
ease, or a positive family history of premature occurrence of 
CVD and/or dyslipidaemia. In patients with acute coronary 
syndrome, lipid profile should be determined within the first 
24 h of onset of symptoms. 
6. LIPID PROFILE DETERMINATION METHODS
The test should be made from plasma or serum of venous 
blood taken in the fasting state, i.e. at least 12 h after the 
last meal [2, 4, 6]. TC, HDL-C, and TG levels are determined 
by the direct method. LDL-C level can be calculated on the 
basis of the Friedewald formula, or determined by the direct 
method (necessary when TG ≥ 4.5 mmol/L, i.e. ≥ 400 mg/dL). 
Evaluation of chylomicronaemia (cold flotation test) should be 
performed if TG concentration is ≥ 10 mmol/L (≥ 900 mg/dL). 
7. TREATMENT GOALS
Treatment goals must take into account the level of car-
diovascular risk (refer to PFP Guidelines on the assessment 
of cardiovascular risk) and it is recommended to achieve 
appropriate levels of LDL-C (primary treatment goal), 
non-HDL-C, and apolipoprotein (apoB) (secondary treat-
ment goals, in the case of hypertriglyceridaemia, metabolic 
syndrome, diabetes mellitus, chronic kidney disease) ac-
cordingly [2, 3].
Treatment goals according to cardiovascular risk:
• Very high risk
 — LDL-C < 1.8 mmol/L (< 70 mg/dL), or a reduction of 
at least 50% if the baseline is between 1.8 mmol/L and 
3.5 mmol/L (70 mg/dL and 135 mg/dL);
 — non-HDL-C < 2.6 mmol/L (< 100 mg/dL);
 — apoB < 80 mg/dL.
• High risk
 — LDL-C < 2.6 mmol/L (< 100 mg/dL), or a reduction of 
at least 50% if the baseline is between 2.6 mmol/L and 
5.1 mmol/L (100 mg/dL and 200 mg/dL);
 — non-HDL-C < 3.3 mmol/L (< 130 mg/dL);
 — apoB < 100 mg/dL.
• Low to moderate risk
 — LDL-C < 3.0 mmol/L (< 115 mg/dL);
 — non-HDL-C < 3.8 mmol/L (< 145 mg/dL).
Regardless of the degree of CVD risk, it is pro-
posed that the following concentrations are obtained: 
fasting TG < 1.7 mmol/L (150 mg/dL) or < 2 mmol/L 
(200 mg/dL); HDL-C in men > 1.0 mmol/L (40 mg/dL), and 
women > 1.2 mmol/L (45 mg/dL), because these levels are 
associated with decreased risk [2, 3]. They are, however, not 
acknowledged as goal values because there is no evidence 
from randomised controlled trials. 
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In all diabetic patients ≥ 40 years of age, initiation of 
statin therapy is recommended (target concentration of LDL-C 
< 1.8 mmol/L; < 70 mg/dL). 
8. NON-PHARMACOLOGICAL TREATMENT
Non-pharmacological interventions should be recommended 
to every patient with dyslipidaemia (Appendix 1) [2, 3]. 
The main recommendations include: dietary modifications, 
physical activity, normalisation of body weight, and tobacco 
abstinence. 
9. PHARMACOLOGICAL TREATMENT
Pharmacotherapy should be considered when diet and 
lifestyle changes do not allow for the achievement of the 
treatment goals and alongside diet in patients with high and 
very high risk.
Hypercholesterolaemia — first-line drugs include HMG-
-CoA reductase inhibitors (statins). The combination therapy 
and the intolerance to statins require the use of selective cho-
lesterol absorption inhibitors (ezetimibe) and anion exchange 
resins. (Colesevelam [resins] is currently unavailable in Poland.)
Inhibitors of PCSK9 may be useful in combination therapy 
with a maximum tolerated dose of statin and ezetimibe in 
patients with FH or in patients with very high cardiovascular 
risk, who fail to achieve treatment goals on statin with ezeti-
mibe. PCSK9 inhibitors may be considered in cases of statin 
intolerance [2, 7].
Hypertriglyceridaemia — the treatment involves the use 
of statins, fibrates, and omega-3 polyunsaturated fatty acids 
(omega-3 PUFAs). Pharmacotherapy should be considered 
if, despite modified lifestyle, TG level exceeds 2.3 mmol/L 
(> 200 mg/dL) and cardiovascular risk is high. Treatment starts 
with a statin and if the TG level still exceeds 2.3 mmol/L the 
addition of fenofibrate and then esters of omega-3 may be 
considered [2].
Low levels of HDL-C — an increase in HDL-C can be 
achieved by using fibrates and statins; however, no therapeutic 
goals were defined [2].
10. MONITORING THE EFFECTIVENESS  
OF TREATMENT AND OF SIDE EFFECTS
Initiation of pharmacotherapy should be preceded by the 
determination of lipid profile, CK, and ALT [2]. The deter-
mination of lipid profile should be performed at least twice 
within 1–12 weeks before therapy initiation, as well as after 
8 ± 4 weeks of its use. Control tests should be performed at 
the same intervals after the change of treatment until target 
lipid levels are achieved. Further controls should take place 
every 12 months [2].
Implementation of treatment monitoring is an essential 
component of treatment of dyslipidaemia.
Rare side effects while taking statins include myopathy 
(0.5%) and increased hepatic enzymes (0.5–2%). Muscle 
pain without increasing CK is reported by up to 10–15% of 
patients [2]. These drugs may increase the risk of developing 
diabetes, but the benefits of using them far outweigh the risk 
(diabetogenic effect mostly concerns patients with fasting 
blood glucose > 100 mg/dL, TG > 150 mg/dL, obesity, 
and history of hypertension). (Experts from the American 
National Lipid Association suggest determination of blood 
glucose or glycated haemoglobin prior to use of a statin and 
during the first year of treatment in patients at increased risk 
for diabetes.)
The risk of myopathy is increased by advanced age and 
some drugs and diseases (Appendix 2) [8].
In the case of myalgia, and if CK is ≥ four times the upper 
normal limit, statin therapy should be stopped immediately, 
kidney function should be checked, and CK monitored every 
two weeks [2]. Indications for withdrawal of therapy or dose 
reduction of statins include intolerable muscle symptoms de-
spite normal levels of CK. It is necessary to inform the patient 
about the warning symptoms such as weakness and/or muscle 
pain, which may occur during therapy. 
Both ALT and CK should be evaluated before starting 
statin therapy, but there is no need to monitor them during 
treatment. Determination of ALT should be performed if 
a patient develops clinical symptoms of hepatotoxicity, such 
as unusual tiredness and weakness, loss of appetite, pain in 
the upper abdomen, dark urine, or jaundice. If ALT levels 
exceed three times the upper normal limit, it is recommen-
ded that statin therapy is discontinued or its dose reduced 
and then retesting after 4–6 weeks. This does not exclude 
cautious reintroduction of therapy after normalisation of 
enzyme activity [2].
Contraindications to statins include: pregnancy, breast-
-feeding, and active liver disease (acute viral hepatitis, 
alcoholic liver disease, decompensated cirrhosis, acute liver 
failure). There is no contraindication to the use of statins in 
the case of chronic liver disease, such as non-alcoholic fatty 
liver disease, non-alcoholic steatohepatitis, chronic hepatitis B 
or C, and primary biliary cirrhosis. 
Before using a fibrate, it is advised to assess kidney fun-
ction (GFR most preferably) and determine ALT. Contraindica-
tions to the use of fibrates include: active liver disease, chronic 
kidney disease stage 5, gallstones, pregnancy, breast-feeding. 
APPENDIX 1 [2, 3]
Non-pharmacological treatment depending on the type 
of dyslipidaemia:
 — Hypercholesterolaemia — it is recommended to replace 
saturated fats, i.e. animal fats, with unsaturated fats, i.e. 
vegetable fats, to avoid the trans-unsaturated fatty acids 
(hydrogenated vegetable oils, for example, hard marga-
rine, ready confectionery), to reduce dietary cholesterol 
intake, and to increase the intake of dietary fibre. The 
use of phytosterols and phytostanols (special margarine, 
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yogurt, and nutritional supplements) can reduce LDL-C 
levels by 10%. 
 — Hypertriglyceridaemia — reduction of excess body 
weight, alcohol consumption (in case of severe hy-
petriglyceridaemia — total alcohol abstinence), con-
sumption of, in particular, mono- and disaccharides 
(sugars, e.g. fructose and sucrose), and reduction of 
total carbohydrates and increase in physical activity 
and the use of preparations with omega 3 fatty acids 
(especially in severe hypetriglyceridaemia). Patients 
with severe hypetriglyceridaemia should be on a very 
low fat diet (fat intake limited to < 10% of total energy 
intake). The recommendation includes both saturated 
and unsaturated fats.
 — Low levels of HDL-C — it is recommended that patients 
increase physical activity, reduce the intake of trans fatty 
acids and carbohydrates, normalise of body weight, and 
stop smoking. 
APPENDIX 2 [8]
Factors that increase the side effects of statins
The risk of myopathy is increased by: 
 — concomitant drug therapy — fibrates (primarily gemfibro-
zil), calcineurin inhibitors (cyclosporine and tacrolimus), 
macrolide antibiotics (azithromycin, clarithromycin, 
erythromycin), azole antifungals (itraconazole, ketocona-
zole), protease inhibitors, calcium antagonists (diltiazem, 
verapamil, mibefradil), sildenafil, acenocoumarol or 
warfarin, digoxin, niacin, and amiodarone (in the case 
of simvastatin and atorvastatin);
 — other factors — female sex, age (> 80 years), low body 
weight, uncompensated hypothyroidism, renal and 
hepatic diseases, alcohol abuse, consumption of high 
quantities of grapefruit juice, vitamin D deficiency, high 
level of physical activity, genetic predisposition, history 
of myopathy due to previous hypolipidaemic treatment, 
idiopathic muscle cramps, history of increased CK, muscle 
symptoms in family.
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